The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study

Abstract Background Studies have indicated that individuals taking aspirin have a reduced risk of cancers and have also established chemo-preventive benefit of aspirin in colorectal cancer. However, research on the association between aspirin use and the survival in patients with lung cancer has rev...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Min-Chun Chuang, Yao-Hsu Yang, Meng-Jer Hsieh, Yu-Ching Lin, Tsung-Ming Yang, Pau-Chung Chen, Ming-Szu Hung
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Aspirin Non–small cell lung cancer Overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cade4eaf15e74cf9866f140e2ebbfcf7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cade4eaf15e74cf9866f140e2ebbfcf7
record_format	dspace
spelling	oai:doaj.org-article:cade4eaf15e74cf9866f140e2ebbfcf72021-11-28T12:27:44ZThe association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study10.1186/s12885-021-08999-81471-2407https://doaj.org/article/cade4eaf15e74cf9866f140e2ebbfcf72021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08999-8https://doaj.org/toc/1471-2407Abstract Background Studies have indicated that individuals taking aspirin have a reduced risk of cancers and have also established chemo-preventive benefit of aspirin in colorectal cancer. However, research on the association between aspirin use and the survival in patients with lung cancer has revealed inconsistent results. In this study, we investigated the effect of aspirin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients. Methods We identified a cohort of 38,842 patients diagnosed with NSCLC between 2000 and 2012 using the Taiwan’s National Health Insurance Research Database and used propensity score matching to reduce possible confounding factors. In total, 9864 patients (4932 matched pairs) were included in the matched cohort. Aspirin exposure was analyzed to identify a possible association with mortality in patients with inoperable NSCLC. Time-dependent Cox regression models were used to calculate the hazard ratios (HRs) and the 95% confidence intervals (95% CIs) that corresponded with aspirin exposure. Results A total of 4979 patients used aspirin at the time of diagnosis of NSCLC. The median overall survival (OS) of the aspirin users was 1.73 (interquartile range, 0.94–3.53) years compared with the 1.30 (interquartile range, 0.69–2.62) years of the non-aspirin users. The Cox proportional hazard model with the time-dependent covariate revealed that aspirin use was associated with a significantly longer OS (HR: 0.83, 95.0% CI: 0.80–0.86). After controlling the sociodemographic characteristics (age, sex, income, and level of urbanization) and lung cancer treatments by propensity score matching, the aspirin users still had a significantly longer OS than the non-aspirin users (HR: 0.79, 95.0% CI: 0.75–0.83). Conclusion Aspirin use is associated with a longer OS in patients with inoperable NSCLC, suggesting that aspirin has a potential anticancer effect. These results warrant further randomized clinical trials to evaluate the actual role of aspirin in the treatment of NSCLC patients.Min-Chun ChuangYao-Hsu YangMeng-Jer HsiehYu-Ching LinTsung-Ming YangPau-Chung ChenMing-Szu HungBMCarticleAspirinNon–small cell lung cancerOverall survivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Aspirin Non–small cell lung cancer Overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Aspirin Non–small cell lung cancer Overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Min-Chun Chuang Yao-Hsu Yang Meng-Jer Hsieh Yu-Ching Lin Tsung-Ming Yang Pau-Chung Chen Ming-Szu Hung The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
description	Abstract Background Studies have indicated that individuals taking aspirin have a reduced risk of cancers and have also established chemo-preventive benefit of aspirin in colorectal cancer. However, research on the association between aspirin use and the survival in patients with lung cancer has revealed inconsistent results. In this study, we investigated the effect of aspirin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients. Methods We identified a cohort of 38,842 patients diagnosed with NSCLC between 2000 and 2012 using the Taiwan’s National Health Insurance Research Database and used propensity score matching to reduce possible confounding factors. In total, 9864 patients (4932 matched pairs) were included in the matched cohort. Aspirin exposure was analyzed to identify a possible association with mortality in patients with inoperable NSCLC. Time-dependent Cox regression models were used to calculate the hazard ratios (HRs) and the 95% confidence intervals (95% CIs) that corresponded with aspirin exposure. Results A total of 4979 patients used aspirin at the time of diagnosis of NSCLC. The median overall survival (OS) of the aspirin users was 1.73 (interquartile range, 0.94–3.53) years compared with the 1.30 (interquartile range, 0.69–2.62) years of the non-aspirin users. The Cox proportional hazard model with the time-dependent covariate revealed that aspirin use was associated with a significantly longer OS (HR: 0.83, 95.0% CI: 0.80–0.86). After controlling the sociodemographic characteristics (age, sex, income, and level of urbanization) and lung cancer treatments by propensity score matching, the aspirin users still had a significantly longer OS than the non-aspirin users (HR: 0.79, 95.0% CI: 0.75–0.83). Conclusion Aspirin use is associated with a longer OS in patients with inoperable NSCLC, suggesting that aspirin has a potential anticancer effect. These results warrant further randomized clinical trials to evaluate the actual role of aspirin in the treatment of NSCLC patients.
format	article
author	Min-Chun Chuang Yao-Hsu Yang Meng-Jer Hsieh Yu-Ching Lin Tsung-Ming Yang Pau-Chung Chen Ming-Szu Hung
author_facet	Min-Chun Chuang Yao-Hsu Yang Meng-Jer Hsieh Yu-Ching Lin Tsung-Ming Yang Pau-Chung Chen Ming-Szu Hung
author_sort	Min-Chun Chuang
title	The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
title_short	The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
title_full	The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
title_fullStr	The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
title_full_unstemmed	The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
title_sort	association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/cade4eaf15e74cf9866f140e2ebbfcf7
work_keys_str_mv	AT minchunchuang theassociationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT yaohsuyang theassociationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT mengjerhsieh theassociationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT yuchinglin theassociationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT tsungmingyang theassociationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT pauchungchen theassociationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT mingszuhung theassociationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT minchunchuang associationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT yaohsuyang associationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT mengjerhsieh associationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT yuchinglin associationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT tsungmingyang associationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT pauchungchen associationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy AT mingszuhung associationofaspirinusewithoverallsurvivalofpatientswithinoperablenonsmallcelllungcanceraretrospectivestudy
_version_	1718407983693561856

The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study

Ejemplares similares